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Bruno Pedro Chumpitazi1,2*, Krupa Mysore1, Cynthia Man-Wai Tsai1 and Robert Jay Shulman1,2,3Abstract
Background: To determine within one tertiary care center: 1) the variation between providers in testing for celiac
disease in children with chronic abdominal pain; 2) the characteristics of those children who were more likely to be
tested, and 3) the prevalence of celiac disease in those evaluated.
Methods: Retrospective review of children with a primary complaint of chronic abdominal pain referred to a
tertiary care children’s hospital for pediatric gastroenterology evaluation over a 2-year period was conducted.
Children with at least two visits and without an identified organic etiology for the pain were included.
Results: 160 children were evaluated by 16 pediatric gastroenterologists and one nurse practitioner. Celiac
serologic testing was completed in 63 (39.4%) children. There was no significant variance in the frequency of celiac
serologic testing between providers. Child age, gender, body mass index, and baseline gastrointestinal symptoms
did not predict whether celiac serologic testing occurred, though Caucasians (P < 0.01) were more likely to be
tested. Eighty-two (51.3%) children underwent either serologic testing and/or esophagogastroduodenoscopy. Four
(4.9%, 95% CI: 1.6-11.3%) of the 82 tested were diagnosed with celiac disease.
Conclusions: Though interprovider variation for celiac disease testing in children with chronic abdominal pain did
not occur, a large number of these children were not evaluated for celiac disease. Children’s race/ethnicity but not
their associated gastrointestinal symptoms predicted whether celiac testing was undertaken. In those tested, celiac
disease was identified in a higher percentage than that expected in the general population.
Keywords: Celiac disease, Children, Abdominal pain, Serology, VariationBackground
Abdominal pain-related functional gastrointestinal disor-
ders (AP-FGIDs) such as irritable bowel syndrome are
prevalent, affecting up to 25% of school-aged children
[1,2]. A child may meet criteria for an established AP-
FGID in the absence of an inflammatory, metabolic, neo-
plastic or anatomic etiology, though identification of an
organic process may depend on whether an evaluation is
undertaken [2].
Celiac disease is an immunologically mediated re-
sponse to gluten, resulting in an inflammatory enterop-
athy [3] and possibly causing gastrointestinal symptoms
such as abdominal pain, constipation, or diarrhea [4].* Correspondence: chumpita@bcm.edu
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distribution, and reproduction in any mediumThese symptoms may overlap with those seen in children
with AP-FGIDs, thereby challenging the clinician caring
for these children to consider the diagnosis of occult celiac
disease. A technical report on chronic abdominal pain in
children suggests most children presenting to primary
care do not require diagnostic testing, including celiac
serologic testing [5]. However, pediatric gastroenterology
practice guidelines for celiac disease in children suggest
celiac disease testing in children with persistent gastro-
intestinal symptoms such as recurrent abdominal pain [6].
To our knowledge, the current practice with respect to
celiac testing by pediatric gastroenterologists evaluating
children with chronic abdominal pain is unknown, and
significant variation in the frequency of testing may exist.
Therefore, we sought to determine the frequency of celiac
disease testing amongst providers at a tertiary care center
for children who would otherwise be determined to have
functional abdominal pain. We were further interested totral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Evaluations and number of children with chronic
abdominal pain undergoing celiac serologic testing by
provider
Provider Children evaluated Celiac serologic testing (%)
Provider #1 32 12 (37.5%)
Provider #2 25 12 (48%)
Provider #3 25 12 (48%)
Provider #4 17 11 (64.7%)
Provider #5 15 7 (46.7%)
Provider #6 11 5 (45.4%)
Provider #7 8 4 (50%)
Provider #8 6 4 (66.7%)
Provider #9 6 4 (66.7%)
Provider #10 4 4 (100%)
Provider #11 2 0 (0%)
Provider #12 2 1 (50%)
Provider #13 2 1 (50%)
Provider #14 2 0 (0%)
Provider #15 1 1 (100%)
Provider #16 1 0 (0%)
Provider #17 1 1 (100%)
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more likely to be tested, and subsequently determine the
prevalence of celiac disease in those evaluated.
Methods
A retrospective chart review, of all children ages 4–
18 years presenting to Texas Children’s Hospital for a
new consultation for abdominal pain in the years 2006
and 2007, was completed. Those who experienced ab-
dominal pain for a minimum of 3 months, returned for
at least one follow-up visit after initial consultation, did
not have celiac serologic testing performed by the refer-
ring primary care physician, and had abdominal pain
entered into the electronic medical record as a pri-
mary diagnosis by the pediatric gastroenterologist were
reviewed. Children who were subsequently diagnosed with
an (potential) organic etiology (e.g. inflammatory bowel
disease) as determined by the primary gastroenterologist,
had any laboratory abnormalities suggesting an organic
etiology, or who had resolution of their symptoms after
starting on a proton-pump inhibitor were excluded. The
remaining children essentially met criteria for an AP-
FGID and were included. The Baylor College of Medicine
Institutional Review Board approved this research study.
Demographic information, co-morbidities (Down syn-
drome, Turner’s syndrome, short stature, autoimmune
hypothyroidism, Type I diabetes mellitus), and baseline
gastrointestinal symptoms (vomiting, bloating, excessive fla-
tus, belching, constipation, diarrhea, >10% weight loss)
were captured from the medical record at the time of the
initial consultation. Celiac serologic testing results (anti-tissue
transglutaminase (TTG) IgA or anti-endomysial (EMA) IgA)
and total serum IgA were obtained from the medical
record. Serological testing was completed at various com-
mercial laboratories as dictated by the children’s health
insurance. Duodenal biopsy reports of children from the
evaluated cohort undergoing esophagogastroduodenoscopy
(EGD) were reviewed. Celiac disease was defined as having
Marsh grade 1 or higher on duodenal biopsies and docu-
mented clinical improvement on a gluten-free diet.
Data were analyzed using SPSS version 19 (Somers,
NY). Chi-square (or Fisher-exact when appropriate) test-
ing was used to compare categorical data between
groups. Fischer-exact testing was used to evaluate vari-
ance in testing frequency between providers. Student’s
t-test was used to compare continuous parametric data
between groups, while Mann–Whitney U was used to
compare continuous non-parametric data between
groups. Data are presented as mean ± standard error of
the mean unless otherwise stated.
Results
160 children were included and were evaluated by 16
pediatric gastroenterologists and one nurse practitioner(Table 1). One hundred fourteen (71.3%) were female,
with mean age at the time of initial consultation being
10.5 ± 3.6 (range 4.1-17.8) years. Mean follow-up length
was 8.0 ± 8.4 months. Self-identified race/ethnicities
included: 66 (41.3%) Caucasian, 41 (25.6%) Hispanic, 10
(6.3%) African-American and 2 Asian (1.3%), with the
remainder considered other or unclassified. Mean BMI%
was 61.8 ± 30.4. Chronic abdominal pain was accompan-
ied by constipation in 69 (43.1%), nausea in 39 (24.4%),
vomiting in 38 (23.8%), diarrhea in 34 (21.3%), flatus
in 19 (11.9%), bloating in 17 (10.6%), >10% weight loss
in 16 (10%), and eructation in 6 (3.8%). One child
had Down syndrome, and one child had Hashimoto’s
thyroiditis with hypothyroidism.
Celiac serologic testing was completed in 63 (39.4%).
Providers did not have a statistically significant variance
(P = 0.15) amongst themselves with respect to the fre-
quency of celiac serologic testing (Table 1). This lack of
statistically significant variance remained when compar-
ing the frequency of serologic testing of the nine pro-
viders evaluating six or more of the included cohort.
Age, gender, and baseline gastrointestinal symptoms did
not predict whether serologic testing was completed
(Table 2). 119 children had a self-identified race of
Caucasian, African-American, Hispanic, or Asian. Of these
children, Caucasian children were more likely than
non-Caucasian children to undergo celiac serologic testing
(35/66 vs. 12/53; P = 0.001). None of the children self-
Table 2 Demographic characteristics and gastrointestinal
symptoms in children undergoing celiac serologic
evaluation versus those who did not
Celiac serology
evaluation (n = 63)
No celiac serology
evaluation (n = 97)
P-value
Age (years) 10.4 ± 3.9 10.6 ± 3.4 .74
BMI% 61.8 ± 28.3 64.2 ± 31.7 .64
Gender Female: 40 (63.5%) Female: 62 (63.9%) .96
Vomiting 14 (22.2%) 24 (24.7%) .71
Nausea 17 (27.0%) 22 (22.7%) .54
Constipation 26 (41.3%) 43 (44.3%) .70
Diarrhea 16 (25.4%) 18 (18.6%) .07
Bloating 10 (15.9%) 7 (7.2%) .08
Flatus 11 (17.5%) 8 (8.2%) .08
Eructation 3 (4.8%) 3 (3.1%) .59
Weight loss 7 (11.1%) 9 (9.3%) .71
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logic testing completed.
Either serologic testing or EGD was performed in 82
(51.3%) of the 160 children with both types of testing be-
ing completed in 20 (12.5%). Celiac serologic testing was
abnormal in 3 children. Two subjects had elevated TTG
IgA antibodies alone (EMA IgA was not tested), and one
subject had both TTG and EMA antibody elevation.
Two different subjects had low IgA levels (one clinically
improved without further investigation whereas the
other underwent an EGD that was negative for celiac
disease). EGD with duodenal biopsies was completed in
39 (24.4%), including the three children with elevated
TTG and/or EMA. Celiac disease ultimately was diag-
nosed in 4 (4.9%; 95% CI: 1.6-11.3%) of the 82 tested with
all 4 having Marsh grade 3 histo-pathologic findings.
When comparing demographic information, BMI%,
and GI symptoms of those undergoing celiac serologic
testing and/or EGD between those found to have celiac
disease vs. those who were not, 3 of 4 (75%) of those
with celiac disease vs. 8 of 78 (10.2%) without celiac
disease had flatus as GI symptom, P < .01. There were
no significant differences seen in any of the other cat-
egories. None of the 4 children with celiac disease had
weight loss.
Discussion
To our knowledge, this is the first study to evaluate indi-
vidual provider variation with respect to celiac testing in
children with chronic abdominal pain. Though intra-
center practice variation amongst providers did not
occur, we found that less than half of these children
underwent celiac serologic testing based upon the prac-
tice of seventeen pediatric gastroenterology providers at
one tertiary care center. When combining both serologictesting and EGD, approximately half of the children
were tested. This lack of uniform testing amongst the
providers for the children evaluated suggests these pro-
viders are selective in their approach; therefore, recom-
mendations regarding uniform celiac testing [6] in this
population are not currently being followed.
Interestingly, we found that age, gender, body mass
index, and gastrointestinal symptoms at the time of the
initial consultation did not predict whether celiac sero-
logic testing was completed. However, being Caucasian
did increase the likelihood of serologic testing. We
hypothesize that this may be due to the fact that providers
recognize that certain high risk human leukocyte antigen
alleles are found more commonly in the Caucasian popu-
lation, with studies suggesting minority populations such
as African Americans comprise only a small percentage
of the celiac disease population in the United States [7,8].
Nevertheless, future investigation into whether race and/
or ethnicity clearly impact the yield of celiac testing in
children with chronic abdominal pain is needed to help
guide providers caring for these patients.
There was a trend toward increased frequency of sero-
logic testing (Table 2) in those children with diarrhea,
bloating, and flatus. Interestingly, flatus was found to
occur significantly more frequently in those with celiac
disease. These symptoms are known to occur in celiac
disease [9], and we note that given this trend toward
testing in children with these symptoms there may be a
higher frequency of celiac disease identified than that
seen in a general population of children with functional
abdominal pain. Further studies are needed to delineate
associated symptoms which may increase the yield of
celiac serologic testing in this population.
Our center’s findings with respect to the overall
intracenter frequency of celiac testing in children with
functional abdominal pain is supported by a previous
study identifying that 57% of 122 children underwent
celiac serologic testing when being evaluated at a tertiary
care medical center for abdominal pain [10]. However,
this study by Dhroove, et al. was limited in that children
with chronic diarrhea, weight loss, and abdominal pain
in particular locations were excluded. Though abdominal
pain in certain locations and weight loss are considered
“red flags” when evaluating a child with chronic abdom-
inal pain [5], children and adults with these symptoms
may still have a functional gastrointestinal disorder,
particularly given a negative evaluation for an organic eti-
ology [11-14]. As such, children with symptoms associated
with celiac disease and functional gastrointestinal disor-
ders were excluded in the Dhroove study. Potentially in
concordance with these limitations, none of the studied
children were subsequently found to have celiac disease,
leading to an estimated prevalence of celiac disease in
their population of chronic abdominal pain below that of
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universal celiac serologic testing supports our findings.
The prevalence of celiac disease in those tested in our
study was higher than that found in a previous pediatric
case–control study using celiac serology alone in the pri-
mary care setting [15]. The prevalence in this previous
study in both those with chronic abdominal pain and
controls was 1% (95% CI: 0-7%) similar to the estimated
prevalence of celiac disease of 1% in the United States
and European general population [3]. The difference in
prevalence between our study and that of Fitzpatrick’s
et al. may be due in part to the usage of EGD biopsy
findings rather than serologic testing alone to make the
diagnosis, and the exclusion of children with other or-
ganic contributors in our final study population (hence
providing for a more selective group). This is supported
by a recent systematic review and meta-analysis that
found the pooled prevalence of celiac in adults with IBS
in studies based upon biopsy-proved celiac disease to be
4.1% (95% CI:1.9-7.0) versus 1.63% (95% CI: 0.7-3.0) in
those studies using serologic testing alone [16]. More-
over, our findings are further supported by a large epide-
miologic screening study using primarily endomysial
antibody testing with intermittent EGD confirmation
which identified a 4.0% (95% CI: 2.99-5.20) prevalence of
celiac disease in 1326 tested symptomatic (abdominal
pain, constipation, diarrhea) children [4].
The primary limitation of this study is its retrospective
nature. As such, initial medical evaluation, serologic test-
ing laboratories, and endoscopies (e.g. number of duo-
denal biopsies taken) were not standardized. Another
limitation is that children were not classified into a spe-
cific Rome III functional gastrointestinal disorder (e.g. ir-
ritable bowel syndrome vs. functional dyspepsia), though
recent studies suggest this may be difficult to do even
with prospective standardized criteria [17]. Finally, this
is a single-center study; therefore, a future multicenter
study is likely needed to confirm its results with respect
to inter-provider variation.
One of the strengths of our study is its basis upon data
generated in routine clinical practice at a tertiary med-
ical center amongst numerous providers, which more
likely reflects the actual experience in this setting and
may help with generalizability of the findings. In evaluat-
ing the prevalence of celiac disease in those tested,
another strength of this study is the use of endoscopic bi-
opsies as part of the diagnostic criteria for celiac disease,
as duodenal biopsy is the gold-standard for diagnosis [3].
All children with positive serologic testing underwent
subsequent EGD; therefore, serologic false positives were
not part of the prevalence determination. Serologic false
negatives influencing the prevalence determination were
decreased in our study as some of the children underwent
EGD despite having negative celiac serology. In fact, onechild in our cohort was identified with celiac disease
despite having negative serologic testing.
Conclusions
Though inter-provider variation for celiac disease testing
in children with chronic abdominal pain did not occur, a
large number of these children were not evaluated for
celiac disease. We found that providers appear to be
selective in their testing with children’s race/ethnicity,
and trends for increased testing with those with diarrhea,
bloating, and flatus. Nevertheless, given the higher preva-
lence of celiac disease found in children who would other-
wise meet criteria for an AP-FGID in our study, we suggest
consideration for celiac disease testing in this population at
this time.
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